Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: A computing device, such as a personal computing device (e.g., laptop, smartphone, etc.) or server, is configured to utilize environmental factors in generating public/private key pairs to access restricted data or operations. The environmental factors can include location, time, barometric pressure, acceleration, temperature, humidity, and the like. An initial key pair may be used to encrypt data and enable other conventional security features. A key pair can be subsequently generated based on the same environmental factors as with the initial key pair generation and used to access the data or operations which have been restricted using the initial key pair.

Abstract: Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of Porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.

Abstract: The present disclosure relates to a spacer for an assembly of a backlight of a display. The disclosure additionally relates to an assembly for a backlight of a display having such a spacer, and to a display having a backlight having such an assembly. The spacer comprises at least one crosspiece. The crosspiece in this case has attachment surfaces for attachment of a first light guide and a second light guide and a receptacle for a sheet stack.

Abstract: A pivotable display system having a traction spring tensioned to reversibly pivot the display around a pivot axis of a shaft connected to an upper portion of a display in a direction from a front side of the display toward the rear side of the display. In the event of an accident-related application of force below a threshold, the display is rotatable in a rearward direction toward an instrument panel, so that a steering column pushed in a direction towards the display avoids or at least reduces the risk of destruction of the display. In the event of accident-related application of force above the threshold, the traction spring may reversibly displace the display upwardly away from the steering column.

Abstract: This invention relates to tetrazoles and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.

Abstract: Fibrous structures, for example sanitary tissue products, such as toilet tissue, and more particularly fibrous structures containing a movable surface and methods for making same and methods for making same are provided.

Abstract: Herein is reported the use of a binding assay of a bivalent, bispecific antibody that has the smaller kD value (dissociation constant) for the interaction with its antigen for the immobilization of the bivalent, bispecific antibody to a solid surface for the determination of the biological activity of the bivalent, bispecific antibody.

Abstract: A display with a two-dimensional display element, which is planar or curved, and an illumination unit for the display element is disclosed. The display has a light source, a light guide and a receiving housing in which the light guide is arranged. The light guide is centered in the middle in its longitudinal direction by means of a centering element in the receiving housing.

Abstract: The present invention relates to a method and an apparatus for measuring the thickness d of a transparent layer (10), and in particular to a method and an apparatus for measuring the thickness d of glass plates during wet-chemical glass thinning in the manufacturing process. The method for measuring the thickness d of a transparent layer (10) includes: determining an approximate thickness dFFT based on a precisely known dispersion n(l) of the material of the layer (10) by performing Fast Fourier Transformation, FFT, analysis on Fabry-Pérot oscillation, FPO, from the layer (10) in a spectral reflectance measurement (900); and performing a FPO full-spectral fitting procedure (910-0) with the approximated thickness dFFT as starting value d0,0 to determine an initial local best fitting thickness dFPO,0.

Abstract: The invention is based on the surprising finding of antibodies that bind to an immunoglobulin-like (Ig) domain of the extra cellular domain (ECD) of IGSF11 (VSIG3) can also inhibit the interaction between IGSF11 and IGSF11 receptors such as VSIR (VISTA), the inhibition of such interaction can provide products, compositions and methods for treating diseases using antigen binding proteins targeting an Ig domain of IGSF11-ECD, including those being inhibitors of IGSF11-interaction with VSIR. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of cell-mediated immune responses, and/or to kill such cells and/or methods for treating proliferative diseases, using an IGSF11 inhibitor such as an antibody binding to an Ig domain of IGSF11-ECD, as well as certain related aspects including detection, diagnostic and screening methods.

Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Abstract: Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.

Abstract: A display comprising a two-dimensional display element, which is planar or curved, and an illumination unit for the display element comprising a light source, a light guide and a receiving housing in which the light guide is arranged is disclosed. The light guide is preloaded in its width direction by at least one clip arranged at one of the longitudinal sides of said light guide.

Abstract: A pedestrian protection feature for a closure latch assembly and method for moving a hood of a motor vehicle to a pop-up position and an open position are provided. The pedestrian protection feature includes an actuator configured to translate a slide cam member to cause a hook to pivot into a striker retaining position to prevent removal of a striker from the closure latch assembly and to pivot a lift lever into engagement with the striker to move the striker toward the hook, whereat the hood is moved to the pop-up position, and optionally a release feature to move the hook from the striker retaining position to a striker releasing position to allow the hood to be moved from the pop-up position to an open position.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: Inducements are provided to customers to regularly connect back to a service provider and report usage that is expressed using a count of requests from a local computing device for cloud-based operations such as packet routing, container instantiation, virtual machine (VM) utilization, calls to a service or application, and the like. The count information is reported within a secure context, such as a trusted execution environment (TEE), using public-private key pair cryptography by which key derivation is dependent on some form of counting. For example, a customer computing device that is subject to a usage license encrypts an operation count and reports it to the service provider.

Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.